(MENAFN- GlobeNewsWire - Nasdaq) Danish English A NNOUNCEMENT NO . 2 3 5
17 April 2023
Appointment of new C E O
ChemoMetec has appointed Rasmus Kofoed as new CEO and he will join no later than 1 August 2023.
Rasmus Kofoed, who is 48 years old, has many years of broad commercial and leadership experience in the medtech and pharmaceutical industries. He comes from a senior position in the listed American company Medtronic, a global leader in healthcare technology solutions. Rasmus Kofoed has most recently been responsible for the company's diabetes business on a large part of the European markets with approx. 270 employees and has been part of the European management team. Prior to that, he held several leading positions within sales and marketing in the companies Roche Diagnostics, Taconic, Abbott as well as several positions in Novo Nordisk for a number of years.
Rasmus Kofoed replaces Steen Søndergaard, who announced his resignment from the position as CEO of ChemoMetec in December 2022.
Together with CFO Niels Høy Nielsen, Rasmus Kofoed will hereafter form the executive management of ChemoMetec.
The Board and the management team at ChemoMetec look forward to welcoming Rasmus Kofoed to ChemoMetec. Over a number of years Rasmus has proved that he is a qualified and engaging leader who achieves results and is capable of developing international organizations with global activities. These skills, combined with the skills of the additional management team at ChemoMetec, will be important drivers in realizing ChemoMetec's ambitious goals for the coming years. This includes both the launch of the upcoming new products, the further development of the markets for ChemoMetec's existing products as well as a general strengthening of the organization.
MENAFN17042023004107003653ID1106024715
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.